Stock Scorecard



Stock Summary for Personalis Inc (PSNL) - $8.38 as of 1/9/2026 3:33:37 PM EST

Total Score

10 out of 30

Safety Score

20 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PSNL

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PSNL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PSNL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PSNL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PSNL (20 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for PSNL

BTIG Reiterates Buy Rating for Personalis (PSNL) with $12 Target 1/9/2026 12:36:00 PM
Personalis expects FY 2025 revenue between $69M and $70M 1/8/2026 7:11:00 PM
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights 1/8/2026 3:11:00 PM
Institutional Investors Are Personalis, Inc.'s (NASDAQ:PSNL) Biggest Bettors and Were Rewarded After Last Week's US$105m Market Cap Gain 1/8/2026 12:36:00 PM
Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone 1/8/2026 8:11:00 AM
Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone 1/7/2026 3:14:00 PM
Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen 1/3/2026 7:08:00 AM
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) 12/30/2025 4:08:00 PM
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) 12/30/2025 10:19:00 AM
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of "Moderate Buy" by Brokerages 12/26/2025 8:09:00 AM

Financial Details for PSNL

Company Overview

Ticker PSNL
Company Name Personalis Inc
Country N/A
Description Personalis, Inc. is a pioneering leader in the field of cancer genomics, headquartered in Menlo Park, California. The company specializes in advanced genomic sequencing and analysis, enabling personalized cancer therapies that enhance precision medicine initiatives. Leveraging its proprietary technology platform, Personalis provides high-quality genomic data that empowers healthcare professionals to make informed treatment decisions. With a growing portfolio of innovative solutions, the company is strategically positioned to transform cancer care through its commitment to data-driven, personalized approaches in oncology.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 8.38
Price 4 Years Ago 14.27
Last Day Price Updated 1/9/2026 3:33:37 PM EST
Last Day Volume 1,175,043
Average Daily Volume 1,408,514
52-Week High 11.40
52-Week Low 2.83
Last Price to 52 Week Low 196.11%

Valuation Measures

Trailing PE N/A
Industry PE 51.88
Sector PE 123.98
5-Year Average PE -5.14
Free Cash Flow Ratio 14.96
Industry Free Cash Flow Ratio 67.47
Sector Free Cash Flow Ratio 29.04
Current Ratio Most Recent Quarter 4.82
Total Cash Per Share 0.56
Book Value Per Share Most Recent Quarter 1.93
Price to Book Ratio 4.13
Industry Price to Book Ratio 15.52
Sector Price to Book Ratio 24.69
Price to Sales Ratio Twelve Trailing Months 10.23
Industry Price to Sales Ratio Twelve Trailing Months 6.44
Sector Price to Sales Ratio Twelve Trailing Months 19.33
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 88,804,000
Market Capitalization 744,177,520
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 24.94%
Reported EPS 12 Trailing Months -0.83
Reported EPS Past Year -0.65
Reported EPS Prior Year -1.37
Net Income Twelve Trailing Months -73,883,000
Net Income Past Year -81,284,000
Net Income Prior Year -108,296,000
Quarterly Revenue Growth YOY -43.60%
5-Year Revenue Growth 5.35%
Operating Margin Twelve Trailing Months -160.70%

Balance Sheet

Total Cash Most Recent Quarter 49,973,000
Total Cash Past Year 91,415,000
Total Cash Prior Year 56,984,000
Net Cash Position Most Recent Quarter 48,739,000
Net Cash Position Past Year 89,769,000
Long Term Debt Past Year 1,646,000
Long Term Debt Prior Year 2,218,000
Total Debt Most Recent Quarter 1,234,000
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 0.99
Total Stockholder Equity Past Year 202,957,000
Total Stockholder Equity Prior Year 129,441,000
Total Stockholder Equity Most Recent Quarter 171,415,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -66,169,000
Free Cash Flow Per Share Twelve Trailing Months -0.75
Free Cash Flow Past Year -46,753,000
Free Cash Flow Prior Year -67,169,000

Options

Put/Call Ratio 0.22
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 4.69
20-Day Bollinger Middle Band 7.91
20-Day Bollinger Upper Band 11.13
Beta 2.00
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 1/10/2026 6:21:13 AM EST